197 related articles for article (PubMed ID: 21511364)
1. [Managing treatment side effects: the respective roles of the active ingredient and the preservative].
Aptel F; Denis P; Baudouin C
J Fr Ophtalmol; 2011 Jun; 34(6):409-12. PubMed ID: 21511364
[TBL] [Abstract][Full Text] [Related]
2. Preservatives in eyedrops: the good, the bad and the ugly.
Baudouin C; Labbé A; Liang H; Pauly A; Brignole-Baudouin F
Prog Retin Eye Res; 2010 Jul; 29(4):312-34. PubMed ID: 20302969
[TBL] [Abstract][Full Text] [Related]
3. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
Baudouin C
Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
[TBL] [Abstract][Full Text] [Related]
4. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe].
Levrat F; Pisella PJ; Baudouin C
J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349
[TBL] [Abstract][Full Text] [Related]
5. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
6. [Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs].
He XG
Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):101-4. PubMed ID: 21426837
[TBL] [Abstract][Full Text] [Related]
7. [Glaucoma and ocular surface].
Stefan C; Cojocaru I; Pop A
Oftalmologia; 2011; 55(1):30-3. PubMed ID: 21774383
[TBL] [Abstract][Full Text] [Related]
8. [Preservatives in eye drops: toward awareness of their toxicity].
Vaede D; Baudouin C; Warnet JM; Brignole-Baudouin F
J Fr Ophtalmol; 2010 Sep; 33(7):505-24. PubMed ID: 20832141
[TBL] [Abstract][Full Text] [Related]
9. [Morphological alterations induced by preservatives in eye drops].
Huber-van der Velden KK; Thieme H; Eichhorn M
Ophthalmologe; 2012 Nov; 109(11):1077-81. PubMed ID: 23179812
[TBL] [Abstract][Full Text] [Related]
10. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
11. Ocular symptoms and signs with preserved and preservative-free glaucoma medications.
Jaenen N; Baudouin C; Pouliquen P; Manni G; Figueiredo A; Zeyen T
Eur J Ophthalmol; 2007; 17(3):341-9. PubMed ID: 17534814
[TBL] [Abstract][Full Text] [Related]
12. [Effects of preservatives in anti-glaucoma agents on the ocular surface].
Potop V
Oftalmologia; 2009; 53(2):92-6. PubMed ID: 19697847
[TBL] [Abstract][Full Text] [Related]
13. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
Erb C; Lanzl I; Seidova SF; Kimmich F
Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of preservative-free and preserved diclofenac and preserved ketorolac eyedrops after cataract surgery.
Maca SM; Amon M; Findl O; Kahraman G; Barisani-Asenbauer T
Am J Ophthalmol; 2010 May; 149(5):777-84. PubMed ID: 20152959
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?
Baudouin C
Int J Clin Pharmacol Res; 1996; 16(1):29-41. PubMed ID: 9001927
[TBL] [Abstract][Full Text] [Related]
16. [Advances in preservative-free glaucoma drops].
Stefan C; Pop A; Cojocaru I
Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063
[TBL] [Abstract][Full Text] [Related]
17. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
[TBL] [Abstract][Full Text] [Related]
18. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
19. Glaucoma therapy and ocular surface disease: current literature and recommendations.
Anwar Z; Wellik SR; Galor A
Curr Opin Ophthalmol; 2013 Mar; 24(2):136-43. PubMed ID: 23542350
[TBL] [Abstract][Full Text] [Related]
20. Side effects of glaucoma medications.
Detry-Morel M
Bull Soc Belge Ophtalmol; 2006; (299):27-40. PubMed ID: 16681086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]